The emergence of antimalarial drug resistance poses a major threat to effective malaria treatment and control in sub-Saharan Africa. The RTS, S/AS01 vaccine has the potential to reduce both resistant infections and antimalarial use. Modeling studies projecting aggregate health burden averted under different scenarios can support further vaccine development and implementation. OHT researchers created a mathematical model that can project cases, drug-resistant infections, and deaths averted from 2021 to 2030 with a vaccine against clinical malaria.